Virtus Biotech Clinical Trials ETF
9 hedge funds and large institutions have $940K invested in Virtus Biotech Clinical Trials ETF in 2025 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 3 closing their positions.
0% more funds holding
Funds holding: 9 → 9 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
13.35% less ownership
Funds ownership: 20.06% → 6.7% (-13%)
44% less capital invested
Capital invested by funds: $1.68M → $940K (-$740K)
86% less call options, than puts
Call options by funds: $17K | Put options by funds: $123K
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$454K |
| 2 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$215K |
| 3 |
DWS
Dynamic Wealth Strategies
Granite Bay,
California
|
+$17.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.05M |
| 2 |
Morgan Stanley
New York
|
-$65.5K |
| 3 |
LPL Financial
San Diego,
California
|
-$24.1K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$10.7K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$4.02K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Jane Street
New York
| $371K | +$454K | +21,149 | New |
|
|
2
LPL Financial
San Diego,
California
| $209K | -$24.1K | -1,125 | -9% |
|
|
3
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| $175K | +$215K | +10,000 | New |
|
|
4
Morgan Stanley
New York
| $148K | -$65.5K | -3,053 | -27% |
|
5
US Bancorp
Minneapolis,
Minnesota
| $17.5K | – | – | – |
|
|
DWS
6
Dynamic Wealth Strategies
Granite Bay,
California
| $14.1K | +$17.2K | +802 | New |
|
|
FDCDDQ
7
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $5.16K | – | – | – |
|
|
AF
8
Allworth Financial
Folsom,
California
| $187 | – | – | – |
|
|
NA
9
NewEdge Advisors
New Orleans,
Louisiana
| $88 | – | – | – |
|
|
10
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$1.05M | -43,735 | Closed |
|
|
11
Osaic Holdings
Scottsdale,
Arizona
| – | -$10.7K | -447 | Closed |
|
|
12
UBS Group
Zurich,
Switzerland
| – | -$4.02K | -168 | Closed |
|
BBC Hedge Fund Activity: Q1 2025 in Review
9 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech Clinical Trials ETF (BBC) for Q1 2025, worth a combined $940K — down 44% from $1.68M a quarter earlier.
Fund positioning in BBC was balanced in Q1 2025: 3 funds opened new positions, 3 closed out, 0 added to existing stakes and 2 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $454K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $1.05M sold.
- 9 institutional investors held Virtus Biotech Clinical Trials ETF (BBC) as of Q1 2025, unchanged from Q4 2024.
- Funds reported $940K of Virtus Biotech Clinical Trials ETF stock for Q1 2025, down 44% quarter-over-quarter.
- 3 funds opened new Virtus Biotech Clinical Trials ETF positions in Q1 2025 and 3 closed out, a net change of 0 holders.
- The largest Virtus Biotech Clinical Trials ETF buyer in Q1 2025 was Jane Street, an estimated $454K added.
- The largest Virtus Biotech Clinical Trials ETF seller in Q1 2025 was Susquehanna International Group, an estimated $1.05M sold.
Based on aggregated 13F filings for Q1 2025.